CL2004001702A1 - Uso de compuestos de formula definida que son antagonistas del receptor v1a de la vasopresina para preparar un medicamento util en el tratamiento de la eyaculacion prematura o eyaculacion rapida. - Google Patents

Uso de compuestos de formula definida que son antagonistas del receptor v1a de la vasopresina para preparar un medicamento util en el tratamiento de la eyaculacion prematura o eyaculacion rapida.

Info

Publication number
CL2004001702A1
CL2004001702A1 CL200401702A CL2004001702A CL2004001702A1 CL 2004001702 A1 CL2004001702 A1 CL 2004001702A1 CL 200401702 A CL200401702 A CL 200401702A CL 2004001702 A CL2004001702 A CL 2004001702A CL 2004001702 A1 CL2004001702 A1 CL 2004001702A1
Authority
CL
Chile
Prior art keywords
ejaculation
treatment
antagonists
receptor
vasopresine
Prior art date
Application number
CL200401702A
Other languages
English (en)
Inventor
Peter Wayman Rache Christopher
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CL2004001702A1 publication Critical patent/CL2004001702A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

LA INVENCION SE REFIERE A UN ENVASE O CAJA ADECUADO PARA COLOCAR UN MEDIO DE INFORMACION/MUSICA TIPO DISCO, QUE COMPRENDE UNA BASE CON UNA SUPERFICIE BASAL PLANA, UNA TAPA O CUBIERTA, UN LOMO QUE INTERCONECTA LA BASE CON LA CUBIERTA. UNA FORMACION RODEADORA SE EXTIENDE DESDE LA SUPERFICIE BASAL PLANA, FORMANDO UNA PARED VERTICAL CIRCULAR. DICHA FORMACION TIENE UNA PRIMERA SUPERFICIE DE CONEXION SOPORTANTE Y UNA SEGUNDA SUPERFICIE DE CONEXION SOPORTANTE, SEPARANDO UNA ABERTURA DICHAS SUPERFICIES DE CONEXION SOPORTANTES PRIMERA Y SEGUNDA. SE DISPON
CL200401702A 2003-07-23 2004-07-06 Uso de compuestos de formula definida que son antagonistas del receptor v1a de la vasopresina para preparar un medicamento util en el tratamiento de la eyaculacion prematura o eyaculacion rapida. CL2004001702A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317227.7A GB0317227D0 (en) 2003-07-23 2003-07-23 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
CL2004001702A1 true CL2004001702A1 (es) 2005-05-13

Family

ID=27772516

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401702A CL2004001702A1 (es) 2003-07-23 2004-07-06 Uso de compuestos de formula definida que son antagonistas del receptor v1a de la vasopresina para preparar un medicamento util en el tratamiento de la eyaculacion prematura o eyaculacion rapida.

Country Status (12)

Country Link
EP (1) EP1656183B1 (es)
JP (1) JP2006528171A (es)
AT (1) ATE380048T1 (es)
BR (1) BRPI0412255A (es)
CA (1) CA2533177A1 (es)
CL (1) CL2004001702A1 (es)
GB (1) GB0317227D0 (es)
MX (1) MXPA05014200A (es)
TW (1) TW200510424A (es)
UA (1) UA79674C2 (es)
WO (1) WO2005006899A1 (es)
ZA (1) ZA200505957B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
ATE412648T1 (de) * 2005-03-21 2008-11-15 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
US20220152032A1 (en) * 2020-11-13 2022-05-19 Pharma America Holding Inc. Sexual therapy formulation and method of treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy

Also Published As

Publication number Publication date
CA2533177A1 (en) 2005-01-27
ZA200505957B (en) 2006-11-29
EP1656183A1 (en) 2006-05-17
WO2005006899A1 (en) 2005-01-27
GB0317227D0 (en) 2003-08-27
MXPA05014200A (es) 2006-07-03
JP2006528171A (ja) 2006-12-14
BRPI0412255A (pt) 2006-09-19
EP1656183B1 (en) 2007-12-05
ATE380048T1 (de) 2007-12-15
TW200510424A (en) 2005-03-16
UA79674C2 (en) 2007-07-10

Similar Documents

Publication Publication Date Title
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
CO6410295A2 (es) Derivados de indol como antagonistas del receptor crth2
CY1113798T1 (el) Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
EA200901099A1 (ru) Соединения и способы модулирования сопряженных с g-белком рецепторов
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
CR9644A (es) Agonistas del receptor de la hormonatiroidea
AR095848A2 (es) Derivados imidazolicos de propionamida moduladores de receptores opioides
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
CO6351782A2 (es) COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA
ECSP055599A (es) AGONISMO DEL RECEPTOR DE 5HT2a PARA EL TRATAMIENTO DE DISFUNCION TERMORREGULADORA
ATE469895T1 (de) Cgrp-rezeptorantagonisten
SV2005002061A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
CL2004000868A1 (es) Compuestos derivados de acidos carboxilicos, antagonistas del receptor de calcio 8casr); composiciones farmaceuticas que comprenden el compuesto, utiles para el tratamiento de osteoporosis.
TW200800959A (en) Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
CL2004000545A1 (es) Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
ECSP067091A (es) Procesos para preparacion de antagonistas de receptor de hormona que libera gonadotropina
ECSP099692A (es) Ligandos de receptor de vainilloide novedosos y su uso de los mismos para la produccion de sustancias farmaceuticas
MA32537B1 (fr) Dérivés de pyrazolo [5,1-b] oxazole en tant qu'antagonistes de crf1
CO2023007404A2 (es) Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina